Business
Distribution Agreement
Distribution Agreement.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \n Avacta Group plc \n\n Appointment of Distributor and Further Optim Sale \n\nAvacta Group plc (\"Avacta\" or the \"Company\"), which provides innovative, high\nvalue proprietary technologies and services to the pharmaceutical and\ndiagnostics markets, is pleased to announce that it has appointed Isogen Life\nScience as distributor in Mainland Europe for the Optim 1000, its\nground-breaking, ultra-low volume protein analysis system.\n\nThe Optim 1000 has been developed to accelerate and reduce the cost of critical\nprotein analysis during pre-formulation, stability testing and formulation of\nbiopharmaceuticals. In these critical areas of drug development the directors\nbelieve that Optim 1000 will deliver vital information tens of times faster\nthan any other known approach using sample sizes more than a hundredth of that\ncurrently needed. This quantum leap in efficiency allows drug developers to\ngain much greater insight into their products at an earlier stage of\ndevelopment which could lead to a significant reduction in later stage failure\nand thus the overall costs of bringing a drug to market. Optim 1000 comprises a\nbench-top instrument and a single-use sample holder which it is expected will\nlead to significant recurring consumables revenues.\n\nIsogen Life Science (ISL), headquartered in De Meern in the Netherlands, is a\nwell established and respected distributor of instruments, reagents and\nconsumables in the areas of cell biology, molecular biology and biochemistry.\nAccordingly, ISL has strong relationships with a large number of\nbiopharmaceutical and biotech customers throughout Europe. Avacta chose Isogen\nas its European distributor for Optim because of this strong track record in\nsales into the biopharmaceutical development area and because of the strong\ncommitment to high quality customer support.\n\nISL has placed an initial order for an Optim 1000 to be placed within a\nEuropean biopharmaceutical research organisation thereby taking the total\nnumber of Optim unit sales todate to five. In the past few months Avacta has\nprogressed a number of potential orders which are expected to reach fruition in\nthe near future as the capital equipment market appears to be recovering from\nrecession. This, combined with the added sales potential of ISL in Europe,\ngives the Directors confidence of achieving th...